In brief: Constipation is a recognised adverse effect of Ozempic, Wegovy and Mounjaro. Check fluids and fibre early, ask a pharmacist or clinician before choosing or increasing a laxative, and do not change the medicine dose on your own. Severe pain, repeated vomiting, signs of dehydration, marked swelling, blood, fever, or inability to pass stool or gas needs urgent medical help.
Constipation during treatment with Ozempic, Wegovy or Mounjaro deserves a plan, not embarrassment.
People using these medicines often eat less and may drink less because they feel full or nauseated. Lower food and fluid intake can change bowel habits. Semaglutide and tirzepatide also delay gastric emptying, but constipation may have several causes and should not automatically be blamed on the medicine.
In the EU, Ozempic is indicated for type 2 diabetes. Wegovy is indicated for weight management under its product criteria. Mounjaro has type 2 diabetes and weight-management indications under its product criteria.
For some people constipation is mild. For others it disrupts eating, comfort and treatment. The aim is to act early while recognising signs that need urgent assessment.
Why constipation can happen
There is rarely one single cause.
Meal size, fibre intake and fluid intake may all fall. Appetite may be low enough that meals become irregular. A sudden large increase in fibre can also worsen bloating.
Current European product information lists constipation as an adverse reaction with semaglutide and tirzepatide medicines. Wegovy product information reports constipation in 24.2% of semaglutide-treated adults and 11.1% of placebo-treated adults across the phase 3a weight-management trials. This figure describes those trials, not every person or every semaglutide dose.
What often helps
Start by checking fluid intake, especially if nausea or reduced appetite has reduced how much you drink. If a clinician has told you to restrict fluids because of heart, kidney or another condition, follow that advice rather than increasing fluids on your own.
Then check fibre. The 2023 American Gastroenterological Association and American College of Gastroenterology guideline supports fibre supplementation for adults with chronic idiopathic constipation, particularly psyllium, but certainty varies by option. Increase fibre gradually because bloating can worsen, and take it with adequate fluid.
Keep protein-rich foods in the plan for muscle support, but do not let them displace fibre-rich foods and fluids. Regular movement remains useful for health and maintenance, although it should not replace medical review when symptoms are significant.
Some people need an over-the-counter laxative. The same guideline supports several options and makes a strong recommendation for polyethylene glycol in adults with chronic idiopathic constipation. However, that guideline was not written specifically for constipation caused by Ozempic, Wegovy or Mounjaro. The right choice depends on your symptoms, health conditions, other medicines, pregnancy or breastfeeding, age, and any history of bowel disease. Ask a pharmacist or clinician which option fits your situation. Do not repeatedly increase laxatives or change your medicine dose without medical advice.
When to contact a clinician
Seek urgent medical help now
Get urgent medical help now if constipation occurs with severe or worsening abdominal pain, repeated vomiting, signs of dehydration, marked abdominal swelling, blood in the stool, fever, or inability to pass stool or gas. These symptoms can signal bowel obstruction or another acute problem. Current Ozempic and Wegovy product information lists intestinal obstruction with frequency not known.
Book a routine medication review
Also contact a clinician if constipation is new and severe but not clearly explained by changes in treatment, eating or fluid intake. This warrants review to rule out other causes.
Seek advice if constipation persists despite basic measures, or if dose escalation repeatedly triggers significant symptoms. Do not stop, restart or change the dose of Ozempic, Wegovy or Mounjaro without discussing it with the prescriber, unless urgent medical staff tell you otherwise.
Why this matters for maintenance
Constipation, nausea and reflux can affect food choices, fluid intake, daily comfort and willingness to continue treatment. Severe symptoms can also make adequate nutrition and muscle-supporting habits harder.
Managing symptoms early supports a plan that remains tolerable during weight loss and realistic for long-term weight maintenance. It also creates a chance to review whether the medicine, dose schedule, nutrition plan and follow-up still fit the patient.
Digestive symptoms need a plan.
At Élan Clinic, we treat digestive symptoms as part of weight maintenance, not as an afterthought. If constipation, nausea, bloating or reflux are making treatment harder, a clinical review can assess likely causes, red flags and suitable next steps.
Book a consultationQuestions patients ask
Is constipation a recognised side effect?
Yes. Current European product information lists constipation among reported gastrointestinal adverse reactions for semaglutide and tirzepatide medicines.
When is it urgent?
Seek urgent medical help now if constipation occurs with severe or worsening abdominal pain, repeated vomiting, signs of dehydration, marked abdominal swelling, blood in the stool, fever, or inability to pass stool or gas. These symptoms can signal bowel obstruction or another acute problem.
Should I keep increasing laxatives?
No. Ask a pharmacist or clinician which option fits your symptoms, health conditions and other medicines. Do not repeatedly increase laxatives or change your Ozempic, Wegovy or Mounjaro dose without medical advice.
Sources
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002. Randomised trial, n=1,961. Constipation was among the gastrointestinal adverse events reported with semaglutide 2.4 mg, the dose studied for Wegovy weight management rather than an Ozempic dose. Funded by Novo Nordisk.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. Randomised trial, n=2,539. Constipation was among the gastrointestinal adverse events reported. Funded by Eli Lilly.
- European Medicines Agency product information for Ozempic, Wegovy, and Mounjaro, accessed August 3, 2026. Official EU indications, delayed gastric emptying, constipation frequency, intestinal obstruction information for Ozempic and Wegovy, and gastrointestinal safety information.
- Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158(5):1232-1249.e3. Clinical review of adult constipation assessment and management.
- Chang L et al. American Gastroenterological Association and American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086-1106. Evidence-based adult guideline covering fibre and over-the-counter pharmacological options.